Reclast (Zoledronic Acid) HSA/FSA Eligibility and Submission: A Complete Guide for Women

Can You Use an HSA or FSA for Reclast (Zoledronic Acid)?

Yes. Reclast (zoledronic acid) is a prescription drug used to treat or prevent osteoporosis, a condition the IRS recognizes as a medical expense under Section 213(d) of the Internal Revenue Code. That means the cost of the drug itself, the infusion administration fee charged by the clinic or infusion center, and the required pre-hydration fluids all qualify as reimbursable expenses through a Health Savings Account (HSA) or Flexible Spending Account (FSA).

Because Reclast is given as a single 15-minute IV infusion once a year, the entire annual cost hits in one billing cycle. That makes strategic HSA/FSA planning especially worth your time.

What Exactly Qualifies

• The zoledronic acid drug itself (brand or generic)
• The infusion administration fee billed by the clinic or hospital outpatient center
• Pre-hydration IV fluids if billed as part of the infusion visit
• Co-insurance and deductible payments made out of pocket for the infusion
• Transportation to and from the infusion center if you are traveling specifically for that medical appointment (mileage at the IRS medical mileage rate for 2025, which is 21 cents per mile)

What Does Not Qualify

Over-the-counter calcium or vitamin D supplements purchased alongside Reclast do not qualify unless they are prescribed by a physician as part of a documented treatment plan. Check with your FSA plan administrator before submitting supplements.

Why Osteoporosis Is a Women's Health Issue First

Osteoporosis is not gender-neutral. Approximately 80 percent of the 10 million Americans with osteoporosis are women, and bone loss accelerates sharply in the first five years after menopause because estrogen normally suppresses osteoclast activity. The estrogen withdrawal of menopause removes that brake.

Zoledronic acid is a nitrogen-containing bisphosphonate that works by binding to bone mineral and inhibiting osteoclast-mediated resorption. In the landmark HORIZON Key Fracture Trial, once-yearly 5 mg zoledronic acid reduced the risk of vertebral fractures by 70 percent and hip fractures by 41 percent over three years in postmenopausal women with osteoporosis. Those are the numbers your bone health plan is built on.

Life-Stage Breakdown

Reproductive years (premenopausal). Zoledronic acid is occasionally prescribed to premenopausal women with glucocorticoid-induced osteoporosis, cancer-treatment-related bone loss, or a documented fragility fracture and low bone density. Prescribing in this group is less common and requires careful attention to contraception (see the pregnancy section below).

Perimenopause. The transition period is when bone density decline begins to steepen. Some women receive a first DEXA scan and a first bisphosphonate prescription during perimenopause. The Menopause Society (formerly NAMS) recommends pharmacologic therapy for postmenopausal women with a T-score of -2.5 or below, or a T-score between -1.0 and -2.5 with a 10-year FRAX hip fracture probability of 3 percent or greater.

Postmenopause. This is the primary indicated population. Zoledronic acid 5 mg IV once yearly is FDA-approved for treatment of postmenopausal osteoporosis. A second indication, 5 mg IV once every two years, covers prevention in postmenopausal women who are not yet at fracture threshold but have declining bone density.

Post-breast-cancer treatment. Aromatase inhibitors (anastrozole, letrozole, exemestane) used for hormone-receptor-positive breast cancer accelerate bone loss. ACOG guidance supports bisphosphonate therapy in women with aromatase inhibitor-associated bone loss when T-score falls below -2.0 or when annual loss exceeds 5 percent. Reclast is often chosen in this setting because the once-yearly schedule reduces burden during active cancer follow-up.

How to Submit an HSA or FSA Claim for a Reclast Infusion

The process differs slightly depending on how the infusion is billed and where it takes place.

Step 1: Get an Itemized Bill

After your infusion, request an itemized Explanation of Benefits (EOB) from your insurer and an itemized receipt from the infusion facility. You need:

• The date of service
• The provider's name and address
• A description of the service (e.g., "zoledronic acid 5 mg IV infusion")
• The amount billed and the amount you owe after insurance

The relevant billing codes you may see on your EOB include CPT 96365 (intravenous infusion, initial up to 1 hour) and HCPCS J3489 or J0776 for zoledronic acid itself. These codes confirm it is a qualifying medical service and drug.

Step 2: Pay With Your HSA or FSA Card at the Point of Service

Many infusion centers accept HSA/FSA debit cards directly. If yours does, swipe and keep your receipt. No further submission is needed, though you should retain the documentation for three years in case of an IRS audit.

Step 3: Submit for Reimbursement If You Paid Out of Pocket

If you paid by personal card, log into your HSA or FSA portal and upload:

1. The itemized receipt or EOB
2. A letter of medical necessity from your prescriber (some plans require this; ask first)
3. Your completed claim form (available from your plan administrator)

Processing takes 5 to 15 business days for most plans.

Step 4: Keep the Prescription Record

Because zoledronic acid is prescription-only, your pharmacy record or prescriber's order satisfies the IRS requirement that the expense be for a prescribed drug or medical service. No additional documentation is normally needed, but a letter from your clinician confirming the diagnosis and the medical necessity of IV therapy can head off questions.

How to Get Reclast or Zoledronic Acid Cheaper

The list price of brand Reclast can reach $1,600 per infusion. Here are concrete strategies to reduce that cost.

Strategy 1: Choose Generic Zoledronic Acid

Generic zoledronic acid entered the U.S. Market in 2016. Multiple FDA-approved generic versions are available, and a 5 mg/100 mL vial may cost $150 to $350 at specialty or infusion pharmacies versus the brand price. Ask your prescriber to write the prescription as "zoledronic acid" rather than "Reclast." Most insurers and pharmacies will substitute the generic automatically, but writing it generically ensures no barrier.

Strategy 2: Compare Site-of-Service Costs

Zoledronic acid can be infused at:

• Hospital outpatient infusion centers (usually the most expensive)
• Physician office infusion suites
• Independent outpatient infusion centers
• Home infusion (available in some markets)

The same infusion can cost three to five times more at a hospital outpatient setting than at a physician office because of the facility fee. CMS data consistently shows hospital outpatient department prices for bisphosphonate infusions running 200-400 percent above non-facility rates.

Ask your prescriber if the order can be routed to a physician office or independent center. Your HSA or FSA will reimburse either setting.

Strategy 3: Meet Your Deductible Strategically

If you have a high-deductible health plan (HDHP), your first infusion of the year will likely apply toward your deductible. If you have met your deductible by, say, October, scheduling the next year's infusion in January puts the cost against a reset deductible. Scheduling it in December instead, after your deductible is met, means insurance pays most of it. Time your infusion with your benefits cycle.

Strategy 4: GoodRx and Cash-Pay Pharmacy Pricing

For the drug vial itself (separate from the infusion fee), GoodRx prices for generic zoledronic acid 5 mg/100 mL range from approximately $180 to $420 depending on pharmacy. Some infusion centers allow you to bring your own drug purchased through a cash-pay pharmacy. Confirm with your center before doing this, as some have policies against it.

Strategy 5: Patient Assistance and State Programs

Novartis does not currently operate a broad open-enrollment patient-assistance program for Reclast as of early 2026, though programs change. The NeedyMeds database and RxAssist list updated programs for generic manufacturers. Some state pharmaceutical assistance programs (SPAPs) cover bisphosphonate infusions for older adults below income thresholds. Check your state's SPAP through the Medicare State Pharmaceutical Assistance Programs page.

Strategy 6: Medicare Coverage

If you are on Medicare, zoledronic acid is covered under Medicare Part B (not Part D) when administered in a physician's office or outpatient clinic, because it is an infusion drug. Standard Medicare Part B cost-sharing is 20 percent after the deductible. That out-of-pocket 20 percent is reimbursable from an HSA if you have one, though note that once you enroll in Medicare you can no longer contribute new money to an HSA. You can still spend existing HSA funds on Medicare cost-sharing.

Pregnancy, Lactation, and Contraception: What You Must Know

Zoledronic acid is contraindicated in pregnancy. This is a hard stop, not a nuanced risk-benefit conversation for most situations.

Pregnancy Risk

Zoledronic acid is classified as FDA Pregnancy Category D based on animal data showing fetal harm including skeletal and other developmental abnormalities. FDA labeling states that zoledronic acid can cause fetal harm when administered to pregnant women. The drug incorporates into bone matrix and may persist there for years, raising a theoretical concern about fetal exposure even after the drug has cleared plasma.

Bisphosphonates cross the placenta in animal models. Human data are limited to case reports and small series. A 2017 systematic review in Osteoporosis International found that bisphosphonate exposure during pregnancy, while generally associated with favorable maternal outcomes, was linked in some cases to transient neonatal hypocalcemia and skeletal changes, though the sample sizes were too small to draw firm safety conclusions.

Who Needs Contraception

Any woman of reproductive potential who receives zoledronic acid must use reliable contraception. The FDA label does not specify a required duration, but because zoledronic acid incorporates into bone and has a skeletal half-life measured in years, many clinicians counsel patients to wait at least 12 months after the last infusion before attempting conception, and some recommend longer intervals. Discuss the specific timeline with your prescriber based on your fracture risk and family planning goals.

Lactation

It is unknown whether zoledronic acid is excreted in human breast milk. Animal studies show excretion in milk. Because of the potential for serious adverse effects in a nursing infant from a drug that binds bone mineral in a developing skeleton, most clinicians recommend against using zoledronic acid while breastfeeding. The LactMed database advises avoiding bisphosphonates during breastfeeding until more data are available.

Premenopausal Women: A Special Note

If you are premenopausal and have been prescribed zoledronic acid for glucocorticoid-induced bone loss, cancer-treatment-related bone loss, or idiopathic osteoporosis, talk with your prescriber about a concrete contraception plan before your first infusion. This is not optional paperwork. It is a necessary clinical step given the drug's long skeletal residence.

Who Is a Good Candidate for Reclast. And Who Is Not.

Good Candidates by Life Stage

Postmenopausal women with a T-score of -2.5 or below. This is the core FDA-approved indication.

Postmenopausal women with a T-score of -1.0 to -2.5 and a FRAX 10-year hip fracture probability at or above 3 percent. The National Osteoporosis Foundation and Menopause Society guidelines support treatment in this range.

Women who cannot tolerate or absorb oral bisphosphonates. Alendronate and risedronate require fasting, staying upright for 30 minutes, and an intact esophagus. Women with GERD, Barrett's esophagus, or malabsorption disorders are often better served by IV zoledronic acid.

Women with documented adherence problems with weekly oral pills. One infusion per year dramatically simplifies the regimen. Adherence to oral bisphosphonates at one year is approximately 50 percent, versus near-complete adherence with an annual infusion.

Women on aromatase inhibitors for breast cancer. Annual IV therapy fits naturally into oncology follow-up schedules.

Not a Good Candidate

• Pregnant women or women actively trying to conceive without a contraception plan in place
• Women with a creatinine clearance below 35 mL/min (significant kidney impairment): FDA labeling contraindicates zoledronic acid in patients with CrCl <35 mL/min
• Women with documented hypocalcemia (must be corrected before infusion)
• Women with a known hypersensitivity to zoledronic acid or any bisphosphonate
• Women with active dental infections or planned invasive dental procedures (due to the risk of osteonecrosis of the jaw, which, while rare, is a recognized complication)

Understanding the Evidence Gap for Women in Subpopulations

Postmenopausal osteoporosis trials are one of the few areas in medicine where women dominate the study populations, so the HORIZON data applies directly to you. But certain subgroups of women remain understudied.

Premenopausal women with low bone density and normal estrogen levels are not well represented in zoledronic acid trials. Most data for that group come from small observational series or from women with clearly defined secondary causes of bone loss such as glucocorticoid use or anorexia nervosa. If you are premenopausal and your clinician is recommending zoledronic acid, ask specifically what evidence base supports the recommendation for your situation, because the answer will likely involve extrapolation from postmenopausal data rather than a directly applicable trial.

Women of color are also underrepresented. Black women have higher bone density on average than white women but are less likely to be screened, less likely to receive treatment when their T-scores meet treatment thresholds, and have not been studied in bisphosphonate trials in numbers that allow subgroup conclusions. A 2021 analysis in JAMA Internal Medicine found that Black women with osteoporosis were 31 percent less likely to receive pharmacologic treatment than white women with the same T-scores. This disparity matters for access planning.

Practical Pre-Infusion Checklist for Women

Before your Reclast or generic zoledronic acid infusion, run through this list.

1. Hydration. Drink at least 500 mL (about 17 oz) of fluid in the two hours before your appointment. Your infusion center may also give you IV fluids before the drug.
2. Calcium and vitamin D status. FDA labeling requires that hypocalcemia be corrected before administration. Ask your clinician to check a basic metabolic panel and 25-OH vitamin D before your infusion if not done recently.
3. Dental health. See your dentist for any needed work before starting bisphosphonate therapy if possible. Once on long-term therapy, invasive dental procedures carry a small risk of osteonecrosis of the jaw.
4. Renal function. A creatinine and eGFR within the past 12 months is standard of care before infusion.
5. HSA/FSA card or documentation. Bring your HSA/FSA debit card or arrange to submit for reimbursement with the itemized receipt.
6. Post-infusion planning. Flu-like symptoms (fever, myalgia, arthralgia, fatigue) occur in up to 32 percent of patients after the first infusion and typically resolve within 72 hours. Acetaminophen taken around the time of infusion reduces this acute-phase reaction. Plan a lighter schedule for the day of and day after your infusion.

PCOS, Endometriosis, and Bone Health: The Connections Worth Knowing

Two common gynecologic conditions affect bone density and intersect with zoledronic acid decisions.

PCOS. Women with PCOS have inconsistent bone density data, with some studies showing protective effects from higher androgen levels and others showing deficits linked to insulin resistance. Low estrogen from oligovulation can reduce bone accrual in adolescence and young adulthood. Women with PCOS who use GnRH agonists for symptom management face an additional estrogen-suppressive hit on bone. Zoledronic acid is not a first-line option in most PCOS patients, but DEXA monitoring is appropriate in women with PCOS on GnRH agonists.

Endometriosis. GnRH agonists such as leuprolide create a medically induced hypoestrogenic state to treat endometriosis. Use beyond six months without add-back hormone therapy leads to measurable bone loss. ACOG recommends add-back therapy for GnRH agonist use beyond six months precisely to mitigate bone effects. If bone loss progresses despite add-back, bisphosphonate therapy including zoledronic acid may be considered.